Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 16.36 -6.99% -1.23
HALO closed down 6.99 percent on Friday, October 19, 2018, on 1.72 times normal volume.

Earnings due: Nov 6

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical HALO trend table...

Date Alert Name Type % Chg
Oct 19 New 52 Week Closing Low Bearish 0.00%
Oct 19 Below Lower BB Weakness 0.00%
Oct 19 Down 3 Days in a Row Weakness 0.00%
Oct 19 Lower Bollinger Band Touch Weakness 0.00%
Oct 18 Fell Below 20 DMA Bearish -6.99%
Oct 18 Fell Below 50 DMA Bearish -6.99%
Oct 17 20 DMA Support Bullish -8.76%
Oct 17 NR7 Range Contraction -8.76%
Oct 17 Inside Day Range Contraction -8.76%
Oct 16 Crossed Above 20 DMA Bullish -9.36%

Older signals for HALO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Is HALO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.48
52 Week Low 16.06
Average Volume 872,774
200-Day Moving Average 18.5006
50-Day Moving Average 17.6292
20-Day Moving Average 17.769
10-Day Moving Average 17.342
Average True Range 0.6165
ADX 18.57
+DI 15.3675
-DI 30.9772
Chandelier Exit (Long, 3 ATRs ) 16.9105
Chandelier Exit (Short, 3 ATRs ) 18.1595
Upper Bollinger Band 18.9387
Lower Bollinger Band 16.5993
Percent B (%b) -0.1
BandWidth 13.165626
MACD Line -0.1313
MACD Signal Line -0.0315
MACD Histogram -0.0998
Fundamentals Value
Market Cap 2.19 Billion
Num Shares 134 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -17.59
Price-to-Sales 16.99
Price-to-Book 39.19
PEG Ratio -2.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.97
Resistance 3 (R3) 18.13 17.75 17.70
Resistance 2 (R2) 17.75 17.34 17.67 17.61
Resistance 1 (R1) 17.06 17.09 16.87 16.90 17.52
Pivot Point 16.68 16.68 16.59 16.60 16.68
Support 1 (S1) 15.99 16.27 15.80 15.83 15.20
Support 2 (S2) 15.61 16.02 15.53 15.11
Support 3 (S3) 14.92 15.61 15.02
Support 4 (S4) 14.76